New pharma genotoxic impurity application note on TSQ Quantis™ LC-MS/MS 
Key benefits
• A single method capable of detecting an azido impurity (AZBT) in six different
Sartan products—Candesartan, Irbesartan, Losartan, Olmesartan, Telmisartan, and Valsartan—saves time by testing multiple products in one sequence without separate
method development.
• A robust method for quantification of AZBT was achieved by using a divert valve to
prevent the mass spectrometer from the build-up of high concentrations of drug
product samples. This helped maintain good sensitivity and reproducibility.
• This study is in line with regulatory information and requirements mentioned in
EDQM1, USFDA (Q2B)2, EMEA3, and ICH M74 guidelines.
an-000748-pb-lc-ms-vanquish-tsq-drug-products-an000748-na-en.pdf (929.1 KB)